Suchen
Unicycive Therapeutics Inc
UNCYZur Watchlist hinzufügen
5.730USD
+0.450+8.52%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
152.99MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unicycive Therapeutics Inc Unternehmen
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc Informationen
BörsenkürzelUNCY
Name des UnternehmensUnicycive Therapeutics Inc
IPO-datumJun 17, 2021
CEOGupta (Shalabh)
Anzahl der mitarbeiter22
WertpapierartOrdinary Share
GeschäftsjahresendeJun 17
Addresse4300 El Camino Real, Suite 210
StadtLOS ALTOS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94022
Telefon16503840642
Websitehttps://unicycive.com/
BörsenkürzelUNCY
IPO-datumJun 17, 2021
CEOGupta (Shalabh)
Führungskräfte von Unicycive Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Unicycive Therapeutics Inc?
Die fünf größten Anteilseigner von Unicycive Therapeutics Inc sind: Dr. Sandeep (Steve) Laumas, M.D.
Wie viele Institutionen halten Anteile an Unicycive Therapeutics Inc (UNCY)?
Mit Stand vom 2026Q1 halten 75 Institutionen Anteile an Unicycive Therapeutics Inc, mit einem Gesamtmarktwert von etwa 9.56M, was 35.81% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 450872.00 gestiegen.